EU regulator starts Moderna's Covid-19 vaccine review

Europe's health regulator has launched a real-time review of US drugmaker Moderna's experimental Covid-19 vaccine, following similar such reviews of rival vaccines from AstraZeneca and Pfizer, news wires reported. The European Medicines Agency’s human medicines committee is evaluating the first batch of data, the regulator said.

Rolling reviews allow drug companies to submit applications for Covid-19 medicinal products before development work is concluded and prior to the availability of complete supporting documentation, aimed at speeding up any approval process. In October, Moderna had said it would apply for real-time reviews of its vaccine in Europe.

EMA’s announcement comes a week after Switzerland began a real-time review of data from Moderna’s vaccine candidate. Moderna said earlier this month that it has enough data for a first interim analysis of its late-stage Covid-19 vaccine trial.

More on this subject: Coronavirus

Similar articles

  • Covid-19 seems to knock out flu across Europe

    Covid-19 seems to knock out flu across Europe

    As Europeans brace for a grim winter with the threat of rising Covid-19 infections, minimal numbers of flu cases recorded so far point to a possible silver lining, Reuters reported. Data available for Europe since the beginning of October, when flu case numbers usually start to ramp up, mirror shallow figures seen in the Southern Hemisphere earlier this year.

  • EMA likely to approve first Covid-19 vaccine on 29 December

    EMA likely to approve first Covid-19 vaccine on 29 December

    The European Medicines Agency (EMA) said on Tuesday it plans to convene an extraordinary meeting on 29 December to decide if there is enough safety and efficacy data about the vaccine developed by Pfizer and BioNTech for it to be approved. The regulator also said it could decide as early as 12 January whether to approve a rival shot by American pharmaceutical company Moderna Inc, which submitted its request to US and European regulators this week.